Sophie L Stocker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3407934/publications.pdf

Version: 2024-02-01

75 papers	2,426 citations	257450 24 h-index	214800 47 g-index
76 all docs	76 docs citations	76 times ranked	3161 citing authors

#	Article	IF	Citations
1	Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2022, 44, 198-214.	2.0	14
2	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2022, 44, 121-132.	2.0	18
3	Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review. International Journal of Pharmacy Practice, 2022, 30, 215-225.	0.6	4
4	Sodiumâ€glucose coâ€transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction. Internal Medicine Journal, 2022, , .	0.8	1
5	Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals. Internal Medicine Journal, 2022, 52, 1135-1143.	0.8	11
6	Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis. Microbiology Spectrum, 2022, 10, .	3.0	7
7	Persistence with urateâ€lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. British Journal of Clinical Pharmacology, 2022, 88, 4894-4901.	2.4	7
8	Review and evaluation of vancomycin dosing guidelines for obese individuals. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 323-335.	3.3	2
9	Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. British Journal of Clinical Pharmacology, 2021, 87, 227-236.	2.4	25
10	Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients. Clinical Microbiology and Infection, 2021, 27, 783.e7-783.e14.	6.0	21
11	Would they trust it? An exploration of psychosocial and environmental factors affecting prescriber acceptance of computerised doseâ€recommendation software. British Journal of Clinical Pharmacology, 2021, 87, 1215-1233.	2.4	14
12	Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?. Therapeutic Innovation and Regulatory Science, 2021, 55, 138-141.	1.6	2
13	A Model Averaging/Selection Approach Improves the Predictive Performance of Modelâ€Informed Precision Dosing: Vancomycin as a Case Study. Clinical Pharmacology and Therapeutics, 2021, 109, 175-183.	4.7	42
14	Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis. Clinical Pharmacology and Therapeutics, 2021, 109, 212-221.	4.7	16
15	Outâ€ofâ€pocket spending among a cohort of Australians living with gout. International Journal of Rheumatic Diseases, 2021, 24, 327-334.	1.9	7
16	Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. British Journal of Clinical Pharmacology, 2021, 87, 1422-1431.	2.4	6
17	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1521-1528.	2.9	5
18	Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6

#	Article	IF	Citations
19	Accuracy of documented administration times for intravenous antimicrobial drugs and impact on dosing decisions. British Journal of Clinical Pharmacology, 2021, 87, 4273-4282.	2.4	11
20	Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. British Journal of Clinical Pharmacology, 2021, 87, 4221-4229.	2.4	16
21	Tacrolimus Therapy in Adult Heart Transplant Recipients. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, 736-746.	2.0	3
22	Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. British Journal of Clinical Pharmacology, 2021, , .	2.4	3
23	Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists. Diabetes Research and Clinical Practice, 2021, 180, 109036.	2.8	13
24	Education to improve vancomycin use: the perspectives of educators and education recipients. Internal Medicine Journal, 2020, 50, 565-572.	0.8	10
25	Researchersâ€™ views on, and experiences with, the requirement to obtain informed consent in research involving human participants: a qualitative study. BMC Medical Ethics, 2020, 21, 93.	2.4	18
26	Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clinical Pharmacokinetics, 2020, 59, 1357-1392.	3.5	29
27	Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure. Journal of Antimicrobial Chemotherapy, 2020, 75, 3293-3302.	3.0	18
28	Australian patient perspectives on the impact of gout. International Journal of Rheumatic Diseases, 2020, 23, 1372-1378.	1.9	7
29	Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. Drug Safety, 2020, 43, 1211-1221.	3.2	24
30	A pharmacokineticâ€pharmacodynamic study of a single dose of febuxostat in healthy subjects. British Journal of Clinical Pharmacology, 2020, 86, 2486-2496.	2.4	4
31	Should the cardioâ€protective properties of sodiumâ€glucose cotransporter 2 inhibitors dictate therapeutic decisionâ€making in patients with type 2 diabetes. Internal Medicine Journal, 2020, 50, 645-646.	0.8	1
32	Better outcomes for patients with gout. Inflammopharmacology, 2020, 28, 1395-1400.	3.9	8
33	The safety and pharmacokinetics of metformin in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 565-575.	3.7	12
34	Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package. Journal of Antimicrobial Chemotherapy, 2020, 75, 1981-1984.	3.0	10
35	Predictors of Success in Gout Treatment. Journal of Rheumatology, 2020, 47, 313-315.	2.0	2
36	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetesâ€”cardiovascular and renal benefits in patients with chronic kidney disease. European Journal of Clinical Pharmacology, 2019, 75, 1481-1490.	1.9	7

#	Article	IF	Citations
37	Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. British Journal of Clinical Pharmacology, 2019, 85, 2772-2783.	2.4	11
38	Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1126-1127, 121764.	2.3	7
39	Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clinical Microbiology and Infection, 2019, 25, 1286.e1-1286.e7.	6.0	96
40	Improving adherence to urateâ€lowering therapy in people living with gout. International Journal of Rheumatic Diseases, 2019, 22, 542-544.	1.9	3
41	Management of gout in older people. Journal of Pharmacy Practice and Research, 2019, 49, 90-97.	0.8	5
42	Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function. Therapeutic Drug Monitoring, 2019, 41, 726-731.	2.0	11
43	Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 45.	2.4	37
44	Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. Current Rheumatology Reports, 2018, 20, 47.	4.7	5
45	Clinical Pharmacokinetics in Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1085-1095.	4.5	142
46	Clinical Pharmacokinetics in Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1254-1263.	4.5	59
47	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics, 2018, 104, 890-899.	4.7	185
48	Usability of Reports Generated by a Computerised Dose Prediction Software. Studies in Health Technology and Informatics, 2018, 252, 27-32.	0.3	5
49	Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 2017, 83, 2015-2026.	2.4	17
50	Allopurinol: insights from studies of doseâ€“response relationships. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 449-462.	3.3	21
51	Characterization of ADME gene variation in 21 populations by exome sequencing. Pharmacogenetics and Genomics, 2017, 27, 89-100.	1.5	43
52	Could metformin be used in patients with advanced chronic kidney disease?. Diabetes, Obesity and Metabolism, 2017, 19, 302-303.	4.4	1
53	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Frontiers in Pharmacology, 2016, 7, 135.	3.5	28
54	Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration. American Journal of Kidney Diseases, 2016, 68, 990-992.	1.9	12

#	Article	IF	Citations
55	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clinical Pharmacokinetics, 2016, 55, 495-506.	3.5	27
56	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clinical Pharmacokinetics, 2016, 55, 711-721.	3.5	47
57	Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin. Molecular Pharmacology, 2015, 88, 75-83.	2.3	88
58	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Annals of the Rheumatic Diseases, 2015, 74, 2157-2164.	0.9	160
59	Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin. Clinical Pharmacology and Therapeutics, 2014, 96, 370-379.	4.7	53
60	Gene Expression Profiling of Transporters in the Solute Carrier and ATP-Binding Cassette Superfamilies in Human Eye Substructures. Molecular Pharmaceutics, 2013, 10, 650-663.	4.6	50
61	Renal Transporters in Drug Development. Annual Review of Pharmacology and Toxicology, 2013, 53, 503-529.	9.4	267
62	Understanding the doseâ€“response relationship of allopurinol: predicting the optimal dosage. British Journal of Clinical Pharmacology, 2013, 76, 932-938.	2.4	33
63	HLA-B*5801 Should Be Used to Screen for Risk of Stevens-Johnson Syndrome in Family Members of Han Chinese Patients Commencing Allopurinol Therapy. Journal of Rheumatology, 2013, 40, 96.2-97.	2.0	10
64	Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8). Journal of Pharmaceutical Sciences, 2013, 102, 3451-3457.	3.3	47
65	The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin. Clinical Pharmacology and Therapeutics, 2013, 93, 186-194.	4.7	157
66	The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology, 2012, 74, 477-489.	2.4	26
67	Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Research and Therapy, 2012, 14, R189.	3.5	32
68	Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?. Internal Medicine Journal, 2012, 42, 411-416.	0.8	44
69	Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout. Journal of Rheumatology, 2011, 38, 904-910.	2.0	56
70	Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. European Journal of Clinical Pharmacology, 2011, 67, 709-713.	1.9	0
71	Measurement of urinary oxypurinol by high performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2363-2368.	2.3	12
72	A proposal for identifying the low renal uric acid clearance phenotype. Arthritis Research and Therapy, 2010, 12, 149.	3.5	14

#	Article	IF	Citations
73	Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid??in Healthy Subjects. Clinical Pharmacokinetics, 2008, 47, 111-118.	3.5	33
74	Optimizing Therapy With Allopurinol: Factors Limiting Hypouricemic Efficacy. American Journal of the Medical Sciences, 2008, 335, 219-226.	1.1	20
75	Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. Clinical Pharmacokinetics, 2007, 46, 623-644.	3.5	153